CONMED Corporation (NYSE:CNMD) Given Average Recommendation of “Reduce” by Brokerages

CONMED Corporation (NYSE:CNMD) has earned a consensus rating of “Reduce” from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $52.8333.

A number of equities research analysts have recently commented on the stock. Bank of America dropped their price objective on shares of CONMED from $65.00 to $52.00 and set a “neutral” rating on the stock in a research note on Monday, December 8th. Wells Fargo & Company increased their price target on shares of CONMED from $41.00 to $42.00 and gave the stock an “equal weight” rating in a report on Thursday. Zacks Research lowered shares of CONMED from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 1st. Piper Sandler decreased their price objective on shares of CONMED from $68.00 to $55.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Finally, JPMorgan Chase & Co. lowered their target price on shares of CONMED from $58.00 to $52.00 and set a “neutral” rating on the stock in a research note on Thursday, November 6th.

CONMED Stock Performance

Shares of CNMD stock opened at $38.30 on Friday. CONMED has a 52-week low of $35.37 and a 52-week high of $74.70. The company has a quick ratio of 0.95, a current ratio of 2.10 and a debt-to-equity ratio of 0.85. The stock has a market cap of $1.19 billion, a PE ratio of 25.36, a price-to-earnings-growth ratio of 1.66 and a beta of 0.96. The business has a 50-day simple moving average of $41.33 and a 200-day simple moving average of $46.33.

CONMED (NYSE:CNMD) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $1.43 earnings per share for the quarter, beating the consensus estimate of $1.32 by $0.11. CONMED had a return on equity of 14.36% and a net margin of 3.42%.The company had revenue of $373.20 million during the quarter, compared to analysts’ expectations of $366.88 million. During the same period last year, the business earned $1.34 earnings per share. CONMED’s quarterly revenue was up 7.9% on a year-over-year basis. On average, equities analysts expect that CONMED will post 4.35 EPS for the current year.

More CONMED News

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q4 results beat analysts: CONMED reported $1.43 EPS (vs. $1.32 est.) and $373.2M revenue (vs. $366.9M est.), with revenue up ~7.9% year-over-year — this is the primary catalyst cited for the stock lift. Conmed: Q4 Earnings Snapshot
• Positive Sentiment: Gross-margin and surgical/orthopedic strength highlighted: coverage notes improved gross margin and outperformance in ortho/surgical segments drove the beat and underpin management’s 2026 outlook. CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up
• Positive Sentiment: Analyst note: Wells Fargo nudged its price target up to $42 (equal-weight), signaling modest upside from current levels and validating the quarter’s credibility. Benzinga
• Positive Sentiment: Management commentary and outlook: call highlights and deep-dive pieces emphasize strategic refocusing and ortho momentum setting the tone for 2026 expectations. CNMD Q4 Deep Dive: Ortho Outperformance and Strategic Refocusing Shape 2026 Outlook
• Neutral Sentiment: Earnings call transcripts and coverage are widely available for deeper read — useful for investors wanting management detail and segment-level commentary. Earnings Call Transcript
• Neutral Sentiment: Street posture mixed: Needham reaffirmed a Hold rating, indicating some analysts remain cautious despite the beat. Benzinga
• Neutral Sentiment: Analyst models: sell-side consensus still implies moderate 2026 earnings (consensus ~4.35 EPS), so follow-through depends on sustained ortho/surgical momentum and margin trends. Compared to Estimates, Conmed (CNMD) Q4 Earnings: A Look at Key Metrics
• Negative Sentiment: Technical/valuation headwinds remain: the stock still trades well below its 52‑week high and under longer-term moving averages, so multiple expansion may be limited absent sustained execution.

Institutional Trading of CONMED

Several institutional investors have recently bought and sold shares of the business. Kelleher Financial Advisors acquired a new position in shares of CONMED during the 3rd quarter worth approximately $28,000. CWM LLC grew its stake in CONMED by 352.0% in the 2nd quarter. CWM LLC now owns 791 shares of the company’s stock valued at $41,000 after acquiring an additional 616 shares during the period. Quarry LP increased its holdings in CONMED by 244.8% in the 3rd quarter. Quarry LP now owns 869 shares of the company’s stock worth $41,000 after acquiring an additional 617 shares in the last quarter. Huntington National Bank increased its holdings in CONMED by 111.8% in the 3rd quarter. Huntington National Bank now owns 883 shares of the company’s stock worth $42,000 after acquiring an additional 466 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in CONMED during the second quarter worth $48,000.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.